The company said total revenues for Q3 2024 were $4,863 million, up 1% as reported. China region revenues fell 22% to $564 million, and the company cited the delayed 2024 stimulus and the ongoing anti-corruption campaign.

1. 01

   The company said total revenues for Q3 2024 were $4,863 million, up 1% as reported. China region revenues fell 22% to $564 million, and the company cited the delayed 2024 stimulus and the ongoing anti-corruption campaign.

2. 02

   GE HealthCare said operating income for Q3 was $676 million, up $59 million, and net income attributable to GE HealthCare was $470 million, with a net income margin of 9.7%. The company said gross profit rose $91 million and cost of products sold fell $43 million.

3. 03

   The company said Adjusted EBIT for Q3 was $795 million, and Adjusted EBIT margin was 16.3%, up $51 million and 90 basis points, respectively. Adjusted net income was $521 million, an increase of $70 million.

4. 04

   GE HealthCare said operating cash flow for the 9 months ended September 30, 2024 was $1,042 million, and free cash flow was $743 million. As of the same date, total debt was $10,312 million. The company issued $1,000 million of senior unsecured notes in Q3.

Key figures

Quarter ended September 30, 2024

Revenue

$4.9B

Operating income

$676M

Net income

$470M

EPS

$1.02

Gross profit

$2.0B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.